Update on multiple sclerosis therapies

There have been major advances in treatment in the past decade.

The past decade has seen rapid advances in drug therapies for MS, each with their own side-effect profile.

multiple sclerosis

MS is a heterogeneous, complex immune-mediated disorder of the central nervous system, affecting about 0.1% of the population in Australia. 

The majority of people (85%) present with the relapsing-remitting form of MS, while others have a progressive disease. The relapsing phase is typified by inflammation and demyelination, while neurodegeneration predominates in the progressive